TGD001 receives Orphan Drug Designation in the United States of America

We are proud to announce that TargED Biopharmaceuticals´ lead investigational therapy, TGD001, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Thrombotic Thrombocytopenic Purpura (TTP). This designation, following a similar approval from the European Medicines Agency (EMA) in 2024, reinforces the potential of TGD001 to address a critical unmet medical need for patients worldwide with this life-threatening blood disorder.